Association between myeloperoxidase levels and risk of coronary artery disease.

CONTEXT Myeloperoxidase (MPO), a leukocyte enzyme that promotes oxidation of lipoproteins in atheroma, has been proposed as a possible mediator of atherosclerosis. OBJECTIVE To determine the association between MPO levels and prevalence of coronary artery disease (CAD). DESIGN, SETTING, AND PATIENTS Case-control study conducted from July to September 2000 in a US tertiary care referral center, including 158 patients with established CAD (cases) and 175 patients without angiographically significant CAD (controls). MAIN OUTCOME MEASURES Association of MPO levels per milligram of neutrophil protein (leukocyte-MPO) and MPO levels per milliliter of blood (blood-MPO) with CAD risk. RESULTS Leukocyte- and blood-MPO levels were both significantly greater in patients with CAD than in controls (P<.001). In multivariable models adjusting for traditional cardiovascular risk factors, Framingham risk score, and white blood cell counts, MPO levels were significantly associated with presence of CAD, with an OR of 11.9 (95% CI, 5.5-25.5) for the highest vs lowest quartiles of leukocyte-MPO and an OR of 20.4 (95% CI, 8.9-47.2) for the highest vs lowest quartiles of blood-MPO. CONCLUSIONS Elevated levels of leukocyte- and blood-MPO are associated with the presence of CAD. These findings support a potential role for MPO as an inflammatory marker in CAD and may have implications for atherosclerosis diagnosis and risk assessment.

[1]  G. Rouleau,et al.  A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. , 2001, American heart journal.

[2]  Jo,et al.  Characterization of a human blood monocyte subset with low peroxidase activity. , 1983, The Journal of clinical investigation.

[3]  Barry Halliwell,et al.  Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils , 1998, Nature.

[4]  A. Daugherty,et al.  Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. , 1994, The Journal of clinical investigation.

[5]  S. L. Hazen,et al.  p-Hydroxyphenylacetaldehyde, an Aldehyde Generated by Myeloperoxidase, Modifies Phospholipid Amino Groups of Low Density Lipoprotein in Human Atherosclerotic Intima* , 2000, The Journal of Biological Chemistry.

[6]  R Peto,et al.  Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. , 1998, JAMA.

[7]  P G Anderson,et al.  Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. , 1994, Biological chemistry Hoppe-Seyler.

[8]  G. Lowe,et al.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. , 2000, The New England journal of medicine.

[9]  S. Hazen,et al.  The Oxidation of Lipoproteins by Monocytes-Macrophages , 1999, The Journal of Biological Chemistry.

[10]  S. Hazen,et al.  Nitric oxide modulates the catalytic activity of myeloperoxidase. , 2000, The Journal of biological chemistry.

[11]  C. V. Smith,et al.  Selective modification of apoB-100 in the oxidation of low density lipoproteins by myeloperoxidase in vitro. , 1999, Journal of lipid research.

[12]  S. Hazen,et al.  Nitric Oxide Is a Physiological Substrate for Mammalian Peroxidases* , 2000, The Journal of Biological Chemistry.

[13]  H. Birkedal‐Hansen,et al.  Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[14]  C. Capeillère-Blandin,et al.  Oxidation of guaiacol by myeloperoxidase: a two-electron-oxidized guaiacol transient species as a mediator of NADPH oxidation. , 1998, The Biochemical journal.

[15]  S. Hazen,et al.  Leukocytes utilize myeloperoxidase-generated nitrating intermediates as physiological catalysts for the generation of biologically active oxidized lipids and sterols in serum. , 1999, Biochemistry.

[16]  J. Heinecke,et al.  Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. , 1994, The Journal of biological chemistry.

[17]  S. Hazen,et al.  Myeloperoxidase-generated oxidants and atherosclerosis. , 2000, Free radical biology & medicine.

[18]  S. Hazen,et al.  Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: pathways for monocyte-mediated protein nitration and lipid peroxidation In vivo. , 1999, Circulation research.

[19]  S. Weiss,et al.  Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[20]  N. Tolbert,et al.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. , 1978, Analytical biochemistry.

[21]  Leukocytes and the risk of ischemic diseases. , 1987, JAMA.

[22]  A. Rebuzzi,et al.  Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. , 1996, Journal of the American College of Cardiology.

[23]  P. Libby,et al.  Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. , 2001, The American journal of pathology.

[24]  H. Rosen,et al.  Antimicrobial activity of myeloperoxidase. , 1984, Methods in enzymology.

[25]  R. Virmani,et al.  A comparison of the Framingham risk index, coronary artery calcification, and culprit plaque morphology in sudden cardiac death. , 2000, Circulation.

[26]  F. Shabani,et al.  The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCI) is suppressed by anti-rheumatic drugs. , 1998, Free radical research.

[27]  G. Francis,et al.  Tyrosyl radical generated by myeloperoxidase catalyzes the oxidative cross-linking of proteins. , 1993, The Journal of clinical investigation.

[28]  H. Rosen,et al.  [52] Antimicrobial activity of myeloperoxidase , 1984 .

[29]  J. Heinecke.  Mass spectrometric quantification of amino acid oxidation products in proteins: insights into pathways that promote LDL oxidation in the human artery wall , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  D. Steinberg,et al.  The oxidative modification hypothesis of atherogenesis: an overview. , 2000, Free radical biology & medicine.

[31]  S. L. Hazen,et al.  Reactive Nitrogen Intermediates Promote Low Density Lipoprotein Oxidation in Human Atherosclerotic Intima* , 1997, The Journal of Biological Chemistry.

[32]  R. Stocker,et al.  Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprotein into a high-uptake form for macrophages. , 1993, The Biochemical journal.

[33]  J. Crowley,et al.  Increased atherosclerosis in myeloperoxidase-deficient mice. , 2001, The Journal of clinical investigation.

[34]  F. Hsu,et al.  Mass Spectrometric Quantification of Markers for Protein Oxidation by Tyrosyl Radical, Copper, and Hydroxyl Radical in Low Density Lipoprotein Isolated from Human Atherosclerotic Plaques* , 1997, The Journal of Biological Chemistry.

[35]  S. L. Hazen,et al.  Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino-acid-derived aldehyde generated by myeloperoxidase, are present in human fatty streaks, intermediate lesions and advanced atherosclerotic lesions. , 2000, The Biochemical journal.

[36]  S. L. Hazen,et al.  3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. , 1997, The Journal of clinical investigation.

[37]  S. Hazen,et al.  p-Hydroxyphenylacetaldehyde Is the Major Product of L-Tyrosine Oxidation by Activated Human Phagocytes , 1996, The Journal of Biological Chemistry.

[38]  J. Schultz,et al.  Studies on the chlorinating activity of myeloperoxidase. , 1976, The Journal of biological chemistry.

[39]  S. Hazen,et al.  Peroxidases inhibit nitric oxide (NO) dependent bronchodilation: development of a model describing NO-peroxidase interactions. , 2001, Biochemistry.

[40]  R. Stockley,et al.  A discrete subpopulation of human monocytes expresses a neutrophil-like proinflammatory (P) phenotype. , 1994, The American journal of physiology.

[41]  D. Kutter,et al.  Consequences of Total and Subtotal Myeloperoxidase Deficiency: Risk or Benefit ? , 2000, Acta Haematologica.

[42]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[43]  S. Hazen,et al.  Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. , 2000, The Journal of clinical investigation.

[44]  R. Stocker,et al.  Immunologic detection and measurement of hypochlorite-modified LDL with specific monoclonal antibodies. , 1995, Arteriosclerosis, Thrombosis and Vascular Biology.

[45]  A. Carr,et al.  Myeloperoxidase binds to low‐density lipoprotein: potential implications for atherosclerosis , 2000, FEBS letters.

[46]  S. Hazen,et al.  Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. , 1999, The Journal of clinical investigation.

[47]  S. Hazen,et al.  Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. , 2000, The Journal of clinical investigation.

[48]  H. Malech,et al.  Primary inherited defects in neutrophil function: etiology and treatment. , 1997, Seminars in hematology.